

The background of the top half of the page is a composite of several elements. On the left, there are overlapping purple and green circular shapes. On the right, there is a photograph of the San Diego skyline at dusk, with the city lights reflecting on the water. A large, faint, light blue circular logo is visible in the upper right quadrant. The text is overlaid on the purple and green shapes.

# ASH 2024

## 66th ASH Annual Meeting and Exposition

December 7–10, 2024  
San Diego, US



## TOP ABSTRACTS

To help navigate the exciting content being presented at the 2024 ASH Annual Meeting, the Lymphoma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

# ASH 2024: Top abstracts in lymphoma and CLL

Saturday, December 7, 2024

Indolent and mantle cell NHL			
Abstract	Title	Speaker	Time (PT)
<b>235</b> <a href="#">View</a>	Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: Results from the international randomised controlled trial, ENRICH	David John Lewis	14:00
<b>240</b> <a href="#">View</a>	Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the randomized TRIANGLE trial by the European MCL network	Martin Dreyling	15:15
<b>338</b> <a href="#">View</a>	Randomized phase III study of watchful waiting vs. rituximab as first-line treatment in patients with advanced stage low tumor burden follicular lymphoma: JCOG1411/FLORA study	Noriko Fukuhara	16:15
<b>339</b> <a href="#">View</a>	Impact of minimal residual disease analysis in the era of rituximab maintenance in follicular lymphoma: Data from "FOLL12" phase III trial of the Fondazione Italiana Linfomi	Simone Ferrero	16:30
<b>340</b> <a href="#">View</a>	Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial	Lorenzo Falchi	16:45
<b>342</b> <a href="#">View</a>	Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the EPCORE NHL-2 trial	Lorenzo Falchi	17:15
<b>1626</b> <a href="#">View</a>	High-risk subgroups and MRD: An updated analysis of the phase III ECHO trial of acalabrutinib with bendamustine/rituximab in previously untreated mantle cell lymphoma	Martin Dreyling	17:30 (poster session)

Hodgkin's lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>1667</b> <a href="#">View</a>	Potential delayed immune-related adverse events in patients treated with frontline pembrolizumab + AVD for classic Hodgkin lymphoma	Thomas Kuczmarski	17:30 (poster session)
<b>1668</b> <a href="#">View</a>	Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma – international, multi-center real-world experience	Efrat Luttwak	17:30 (poster session)
<b>2346</b> <a href="#">View</a>	Estimation of health state utility values for patients undergoing first-line treatment of advanced-stage classical Hodgkin lymphoma in the HD21 trial	Ajibade Ashaye	17:30 (poster session)

# ASH 2024: Top abstracts in lymphoma and CLL

## Saturday, December 7, 2024 (continued)

Aggressive B-cell non-Hodgkin lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>91</b> <a href="#">View</a>	Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma	Mingming Zhang	09:30
<b>111</b> <a href="#">View</a>	Real-world outcomes with bispecific T-cell engagers (REALBiTE) for relapsed or refractory large B-cell Lymphoma: A Multi-center, retrospective cohort study	Taylor R. Brooks	10:00
<b>72</b> <a href="#">View</a>	Circulating tumor DNA (ctDNA) as an early outcome predictor in patients (pts) with second-line (2L) large B-cell lymphoma (LBCL) after lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) treatment (tx) from the phase III, randomized TRANSFORM study	Ash A. Alizadeh	10:45
<b>114</b> <a href="#">View</a>	Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma	Evgenii Shumilov	10:45
<b>389</b> <a href="#">View</a>	Safety and efficacy of chimeric antigen receptor T-cell therapy in octogenarian patients (aged ≥ 80) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)	Dasom Lee	16:15

Chronic lymphocytic leukemia/small lymphocytic lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>1867</b> <a href="#">View</a>	Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naïve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400)	Jacob D. Soumerai	17:30 (poster session)
<b>1869</b> <a href="#">View</a>	Consistently high 5.5-year progression-free survival (PFS) rates in patients with and without bulky baseline lymphadenopathy ≥5 cm are associated with high undetectable minimal residual disease (uMRD4) rates after first-line treatment with fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase II CAPTIVATE Study	William G. Wierda	17:30 (poster session)

## Sunday December 8, 2024

Indolent and mantle cell NHL			
Abstract	Title	Speaker	Time (PT)
<b>3031</b> <a href="#">View</a>	Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase III ASPEN study: A report from the zanubrutinib extension study	Shirley D'Sa	18:00 (poster session)
<b>3034</b> <a href="#">View</a>	Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase II ELARA 4-year update	Catherine Thieblemont	18:00 (poster session)

# ASH 2024: Top abstracts in lymphoma and CLL

Sunday, December 8, 2024 (continued)

T-cell lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>463</b> <a href="#">View</a>	Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma	Alison Moskowitz	09:30
<b>466</b> <a href="#">View</a>	Health-related quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma treated by lacutamab: Patient-reported outcomes from the phase II TELLOMAK trial	Pierluigi Porcu	10:15
<b>468</b> <a href="#">View</a>	Randomized phase II trial of the anti-PD-L1 monoclonal antibody durvalumab plus lenalidomide versus single-agent durvalumab in patients with refractory/advanced cutaneous T cell lymphoma	Christiane Querfeld	10:45

Hodgkin's lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>460</b> <a href="#">View</a>	Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma	Jeremy S. Abramson	10:15
<b>461</b> <a href="#">View</a>	Omission of bleomycin in limited stage classic Hodgkin lymphoma patients with a negative PET scan following 2 cycles of ABVD is associated with comparable outcomes and reduced pulmonary toxicity	Jiayu Yang	10:30
<b>462</b> <a href="#">View</a>	Pembrolizumab in children, adolescents, and young adults with low-risk classic Hodgkin lymphoma (cHL) and slow early response to front-line chemotherapy: Updated results from the phase II KEYNOTE-667 study	Lisa Giulino Roth	10:45
<b>569</b> <a href="#">View</a>	Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin	Alison Moskowitz	13:00
<b>3045</b> <a href="#">View</a>	Brentuximab vedotin (BV) and nivolumab (nivo) for untreated patients with Hodgkin lymphoma (HL): Long-term results	Bruce D. Cheson	18:00 (poster session)
<b>3053</b> <a href="#">View</a>	Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma	Robert Stuver	18:00 (poster session)

# ASH 2024: Top abstracts in lymphoma and CLL

Sunday, December 8, 2024 (continued)

Aggressive B-cell non-Hodgkin lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>469</b> <a href="#">View</a>	Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes	Gilles Salles	09:30
<b>470</b> <a href="#">View</a>	Real-world (RW) outcomes of lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): First results from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry	Maria Silvina Odstrcil Bobillo	09:45
<b>526</b> <a href="#">View</a>	Real-world early outcomes of second-line axicabtagene ciloleucel (axi-cel) therapy in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)	Dasom (Caroline) Lee	10:15
<b>527</b> <a href="#">View</a>	Real-world trends of cytokine release syndrome and neurologic events, and pattern of their management among patients receiving axicabtagene ciloleucel for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the US: A CIBMTR report	Jiasheng Wang	10:30
<b>575</b> <a href="#">View</a>	Outcomes of primary mediastinal B-cell lymphoma patients treated with a PET-guided strategy in the randomized phase III gained study conducted by Lysa	Vincent Camus	13:00
<b>577</b> <a href="#">View</a>	Final Analysis of the safety and efficacy of venetoclax in combination with Pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma	Catherine S. Diefenbach	12:00
<b>607</b> <a href="#">View</a>	Tisagenlecleucel for the management of patients with relapsed/refractory diffuse large B-cell lymphoma: An interim report of the European post-authorisation safety study conducted by EBMT	Christian Chabannon	12:00
<b>579</b> <a href="#">View</a>	Golcadomide (GOLCA) plus R-CHOP has high minimal residual disease (MRD) negativity across high-risk, untreated aggressive B-cell lymphoma (a-BCL)	Jason R. Westin	12:30
<b>581</b> <a href="#">View</a>	Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features: Long-term results from the EPCORE NHL-2 TRIAL	Lorenzo Falchi	13:00
<b>582</b> <a href="#">View</a>	A randomized phase II, investigator-led trial of glofitamab-R-CHOP or glofitamab-polatuzumab vedotin-R-CHP (COALITION) in younger patients with high burden, high-risk large B-cell lymphoma demonstrates safety, uncompromised chemotherapy intensity, a high rate of durable remissions, and unique FDG-PET response characteristics	Adrian Minson	13:15
<b>2336</b> <a href="#">View</a>	Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)	Varun Iyengar	17:30 (poster session)

# ASH 2024: Top abstracts in lymphoma and CLL

## Sunday, December 8, 2024 (continued)

Chronic lymphocytic leukemia/small lymphocytic lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>584</b> <a href="#">View</a>	Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk : Final results of the ERADIC trial from the Filo group	Anne Sophie Michallet	12:15
<b>585</b> <a href="#">View</a>	IGHV unmutated status, low tumor lysis risk disease and BRAF mutated status are predictors for early MRD responders treated with MRD defined ibrutinib with venetoclax: Report of the UK NCRI FLAIR study	Talha Munir	12:30
<b>3249</b> <a href="#">View</a>	Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL): 5-year follow-up of cohort 1 from the SEQUOIA study	Mazyar Shadman	18:00 (poster session)
<b>3251</b> <a href="#">View</a>	Acalabrutinib versus chlorambucil plus rituximab in patients with previously untreated chronic lymphocytic leukemia: A randomized, multicenter, open-label, phase III study	Lugui Qiu	18:00 (poster session)

## Monday, December 9, 2024

Indolent and mantle cell NHL			
Abstract	Title	Speaker	Time (PT)
<b>859</b> <a href="#">View</a>	Bortezomib in combination with ibrutinib/rituximab is a highly effective and well tolerated first – line treatment for Waldenström’s macroglobulinemia: results of the multicenter phase II trial (ECWM-2) of the European Consortium for Waldenström’s macroglobulinemia	Christian Buske	14:45
<b>861</b> <a href="#">View</a>	Iopofosine I 131 in previously treated patients with Waldenström macroglobulinemia (WM): Efficacy and safety results from the international, multicenter, open-label phase II study (CLOVER-WaM™)	Sikander Ailawadhi	15:15
<b>862</b> <a href="#">View</a>	Efficacy and safety of odronextamab in relapsed/refractory marginal zone lymphoma (R/R MZL): Data from the R/R MZL cohort in the ELM-2 study	Tae Min Kim	15:30
<b>864</b> <a href="#">View</a>	5-year follow-up analysis from ZUMA-5: A phase II trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma	Sattva S. Neelapu	16:00
<b>4388</b> <a href="#">View</a>	Five-year outcomes of patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 cohorts 1 and 2	Michael Wang	18:00 (poster session)



# ASH 2024: Top abstracts in lymphoma and CLL

Monday, December 9, 2024 (continued)

Aggressive B-cell non-Hodgkin lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>865</b> <a href="#">View</a>	Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study	Michael J. Dickinson	14:45
<b>866</b> <a href="#">View</a>	Efficacy and safety of odronextamab monotherapy in patients (pts) with diffuse large B-cell lymphoma (DLBCL) progressing after CAR T-cell therapy: Primary analysis from the ELM-1 study	Matthew Matasar	15:00
<b>867</b> <a href="#">View</a>	EPCORE DLBCL-3 first disclosure: Fixed-duration epcoritamab monotherapy in older (≥75 y), anthracycline-ineligible patients with previously untreated large B-cell lymphoma	Franck Morschhauser	15:15
<b>869</b> <a href="#">View</a>	Longer follow-up of golcadomide (GOLCA), a cereblon E3 ligase modulator (CELMoD™) agent ± rituximab (RTX), in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)	Jean-Marie Michot	15:45
<b>957</b> <a href="#">View</a>	BMS-986458 a potential first-in-class, highly selective, potent and well tolerated BCL6 ligand directed degrader (LDD) demonstrates multi-modal anti-tumor efficacy for the treatment of B-cell non-Hodgkin's lymphoma	Lynda Groocock	17:00
<b>988</b> <a href="#">View</a>	Glofitamab in combination with polatuzumab vedotin maintains durable responses and a manageable safety profile in patients with heavily pre-treated relapsed/refractory (R/R) large B-cell lymphoma (LBCL) including high-grade B-cell lymphoma (HGBCL): Extended follow-up of a phase Ib/II study	Martin Hutchings	17:15
<b>4483</b> <a href="#">View</a>	Outcomes in older patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) from the ECHELON-3 study	Nancy L. Bartlett	18:00 (poster session)
<b>4474</b> <a href="#">View</a>	A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign	Pallawi Torka	18:00 (poster session)
<b>5132</b> <a href="#">View</a>	Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the phase III STARGLO study	Gareth P. Gregory	18:00 (poster session)

# ASH 2024: Top abstracts in lymphoma and CLL

## Monday, December 9, 2024 (continued)

Chronic lymphocytic leukemia/small lymphocytic lymphoma			
Abstract	Title	Speaker	Time (PT)
<b>883</b> <a href="#">View</a>	Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): Results from CLL expansion and optimization cohorts of EPCORE CLL-1	Alexey Danilov	14:45
<b>886</b> <a href="#">View</a>	BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma	Jeff P. Sharman	15:30
<b>887</b> <a href="#">View</a>	Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary results from the open-label, phase I/II TRANSCEND CLL 004 study	William G. Wierda	15:45
<b>1009</b> <a href="#">View</a>	Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase III AMPLIFY trial	Jennifer R. Brown	16:30
<b>1010</b> <a href="#">View</a>	Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)	Meghan C. Thompson	16:45
<b>1011</b> <a href="#">View</a>	Combined pirtobrutinib, venetoclax, and obinutuzumab as first-line treatment of patients with chronic lymphocytic leukemia (CLL)	Nitin Jain	17:00
<b>4633</b> <a href="#">View</a>	Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Updated follow-up of TRANSCEND CLL 004	Tanya Siddiqi	18:00 (poster session)

## Tuesday, December 10, 2024

Indolent and mantle cell NHL			
Abstract	Title	Speaker	Time (PT)
<b>LBA1</b> <a href="#">View</a>	Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase III study (inMIND)	Laurie H. Sehn	07:30
<b>LBA6</b> <a href="#">View</a>	Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): Initial report from the ECOG-ACRIN EA4151 phase III randomized trial	Timothy S. Fenske	07:30





**#ASH24**

Follow us on X to keep up to date  
with the latest from the congress

**@lymphomahub**



Brought to you by

